Buys | $0 | 0 | 0 |
Sells | $110,547 | 1 | 100 |
Drutz David | director | 0 | $0 | 1 | $110,547 | $-110,547 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known …
Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $7.62M and sold $897,547 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.
2024-08-19 | Sale | Drutz David | director | 16,011 0.0206% | $6.90 | $110,547 | -8.49% | |
2023-08-15 | Drutz David | director | 300 0.0006% | $2.88 | $863 | +145.20% | ||
2023-03-24 | Eisenstadt Richard I | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | ||
2023-03-23 | Harris Matthew Scott | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | ||
2023-03-23 | Drutz David | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | ||
2022-12-22 | Sale | Pisano Wayne | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | |
2022-08-30 | Sale | Garg Vipin K | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | |
2022-08-12 | Sale | Garg Vipin K | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.92% | |
2022-08-12 | Sale | GILL JOHN | director | 2,714 0.0048% | $15.00 | $40,710 | -39.92% | |
2022-07-01 | Sale | Roberts M Scot | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | |
2022-06-29 | Sale | Roberts M Scot | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | |
2022-06-27 | Sale | Roberts M Scot | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | |
2022-06-27 | Sale | Jorkasky Diane | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | ||
2022-06-15 | Drutz David | 1,000 0.002% | $8.00 | $8,000 | +36.66% | |||
2022-05-24 | Drutz David | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | |||
2022-02-28 | Sale | Harris Matthew Scott | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | |
2021-03-01 | Sale | Hodges Philip | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | |
2020-12-10 | Schafer Klaus | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% | ||
2020-12-01 | Sale | Hodges Philip | director | 1,227 0.0047% | $13.54 | $16,614 | -6.30% | |
2020-11-30 | Sale | Hodges Philip | director | 2,500 0.0096% | $12.00 | $30,000 | +6.26% |
Drutz David | director | 41958 0.0545% | $218,181.60 | 6 | 1 | +43.65% |
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 8.6042% | $34.46M | 1 | 3 | |
EVNIN LUKE | 10 percent owner | 6347614 8.2422% | $33.01M | 2 | 0 | |
MPM BIOVENTURES III LLC | 10 percent owner | 6347614 8.2422% | $33.01M | 2 | 0 | |
Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 5.8431% | $23.4M | 4 | 0 | +64.5% |
$84,871,118 | 57 | 17.71% | $406.62M | |
Altimmune, Inc. (ALT) | $24,384,691 | 42 | -30.27% | $400.47M |
$26,923,982 | 20 | -17.22% | $415.61M | |
$73,222,926 | 18 | 60.19% | $406.77M | |
$276,750,010 | 16 | -7.95% | $381.52M |
Increased Positions | 102 | +58.29% | 5M | +13.58% |
Decreased Positions | 69 | -39.43% | 4M | -10.63% |
New Positions | 38 | New | 870,626 | New |
Sold Out Positions | 24 | Sold Out | 1M | Sold Out |
Total Postitions | 208 | +18.86% | 41M | +2.95% |
Blackrock, Inc. | $40,959.00 | 8% | 6.16M | +693,211 | +12.68% | 2024-12-31 |
Ameriprise Financial Inc | $34,945.00 | 6.83% | 5.25M | +1M | +35.57% | 2024-12-31 |
Vanguard Group Inc | $29,470.00 | 5.76% | 4.43M | -552,246 | -11.08% | 2024-12-31 |
State Street Corp | $23,076.00 | 4.51% | 3.47M | +56,190 | +1.65% | 2024-12-31 |
Tang Capital Management Llc | $18,288.00 | 3.57% | 2.75M | 0 | 0% | 2024-12-31 |
Geode Capital Management, Llc | $11,029.00 | 2.15% | 1.66M | -9,498 | -0.57% | 2024-12-31 |
Knoll Capital Management, Llc | $7,458.00 | 1.46% | 1.12M | 0 | 0% | 2024-12-31 |
Bellevue Group Ag | $6,287.00 | 1.23% | 945,446 | +81,786 | +9.47% | 2024-12-31 |
Morgan Stanley | $6,130.00 | 1.2% | 921,822 | -373,763 | -28.85% | 2024-12-31 |
Ubs Group Ag | $4,785.00 | 0.93% | 719,555 | +437,100 | +154.75% | 2024-12-31 |